Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia

Summary

This study aims to evaluate the safety and clinical activity of CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in treating patients with recurrent or refractory CD19 positive B cell ccute lymphoblastic leukemia,and dynamically observe the changes of CAR-T in patients and the residual tumor.

Timeline

Start

2019-05-01

Primary completion

2020-12-30

Completion

2021-12-30

Drugs

Indications